With a contrarian and deep-value based investing philosophy, Asclepia identifies core holdings that consist of companies largely under-the-radar, unloved, underappreciated, and undervalued by the investment community. They also obtain price target objectives within a twelve-to-eighteen month timeframe. While core holdings may experience volatility along the way, performance volatility is mitigated by trading positions, which consist of companies with a three-to-six month timeframe and an undervalued thesis based on more than just fundamental reasons. This mix of core holdings and trading positions are hedged by a basket of short positions and/or index options and allow us to maintain a competitive advantage over our peers in both up and down markets.
INVESTING IN THE INNOVATION OF SCIENCE
The Asclepia Capital Fund, LP invests in innovative biotech and life science companies, or modern-day "Asclepia" (healing temples) in the US and Europe.
The Fund's fifteen to twenty-five holdings are growth in nature, and consist of companies balanced mostly across micro, small, and mid capitalizations, undergoing a rigorous due diligence process based on bottom-up style of analysis.